MISSISSAUGA, Ontario, March 31, 2022 (GLOBE NEWSWIRE) — BioSyent Inc. (“BioSyent” or the “Company”, TSX Venture: RX) announces that its Board of Directors has approved a grant of 56,957 Restricted Share Units “RSUs” to certain directors, officers, management, and employees of the Company pursuant to the Company’s Restricted Share Unit Plan (the “RSU Plan”). These RSUs will fully vest within three years on the third anniversary of the applicable grant date. About BioSyent Inc. Listed on the TSX Venture Exchange under the trading symbol “RX”, BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical and other healthcare products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients. BioSyent supports the healthcare professionals that treat these patients by marketing its products through its community, specialty and international business units. As of the date of this press release, the Company has 12,414,358 common shares outstanding. For a direct market quote for the TSX Venture Exchange and other Company financial information please visit www.tmxmoney.com. For further information please contact:Mr. René C. GoehrumPresident and CEOBioSyent Inc.E-Mail: investors@biosyent.comPhone: 905-206-0013Web: www.biosyent.com This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory approvals. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.